1. Home
  2. Shareholder and Investor Information
  3. The first result of assessment of small molecule protein-protein interaction (PPI) inhibitors identified by the collaborative research between RaQualia and Interprotein

Shareholder and Investor Information

The first result of assessment of small molecule protein-protein interaction (PPI) inhibitors identified by the collaborative research between RaQualia and Interprotein

September 2, 2013 – RaQualia Pharma Inc. (RaQualia) and Interprotein Corporation (Interprotein) today announced the first result of assessment of small molecule protein-protein interaction (PPI)* inhibitors that were identified by the collaborative research between RaQualia and Interprotein.

 

The present research was conducted under the collaborative research agreement that has been announced on February 1st, 2013.  Interprotein designed hit candidates using the platform technology, INTENDD, and RaQualia assessed the compounds in a cell-based assay system originally established at its own laboratory.  As a result, 49 of 273 (approximately 18%) compounds tested were identified as hit compounds that met the criteria.

 

Based on the present result, Interprotein will receive the first contingency payment from RaQualia, and both companies will collaborate to identify drug candidates for the disease domain of pain in succession under the agreement.

 

 *About PPI:

Protein-protein interaction (PPI) is the general term of biological responses that are produced by binding of two or more protein molecules.  For instance, it indicates a binding of cytokine to its receptor followed by intracellular signal transduction from the receptor.  Thus, PPI plays an important role in the pathophysiology of many diseases.

 

About RaQualia:

RaQualia Pharma Inc. is an innovative life science company engaging in the discovery, development and marketing of clinical and pre-clinical candidates for unmet medical needs worldwide. For additional information, please visit www.raqualia.com

 

About Interprotein:

Interprotein is focusing on research and development of small molecule medicines based on unique in silico molecular design strategy, INTENDD (INTerprotein's Engine for New Drug Design).  INTENDD consists of identification of small molecule binding site with real 3D molecular models and in silico screening with SBSG (Structure-Based Scaffold Generation) method, and exercise its power over drug discovery research of not only PPI inhibitors but also non-PPI inhibitors.

####

 

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics